Innate Pharma has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca. The collaboration is to evaluate the combination of Innate Pharma’s first-in-class IPH5401 antibody and Imfinzi (durvalumab) in a Phase I/II study for patients with selected solid tumors.    The Phase I/II study (STELLAR-001) will evaluate the safety and efficacy of durvalumab, an anti-PD-L1 immune checkpoint inhibitor, in combination with ...